Skip to content
drillr.ai
Sign up
ResearchBMRN

[BMRN] BioMarin Pharmaceutical Thesis 2026: Voxzogo Achondroplasia Drives Roctavian Hemophilia Pipeline

Ddrillr ResearchOriginal research
Published 10 min read

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) FY2025 revenue ~$3.05-3.20B (+15-22%) with adj. EPS ~$3.85-4.20 reflecting continued post-2024 ~$870-925M aggregate Voxzogo (vosoritide; achondroplasia) revenue (~28%+ aggregate revenue mix; selected primary post-November 2021 EU + FDA approval) + selected continued post-2024 ~$1.85-1.95B aggregate Legacy enzyme replacement therapy (ERT) + small-molecule revenue (~62% aggregate revenue mix; selected primary Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) + selected continued post-2024 ~$310-360M aggregate Roctavian + selected various aggregate Other (~10% aggregate revenue mix) under continued President + CEO Alexander Hardy since November 2023 (~2-year tenure as BioMarin CEO). US specialty rare genetic disease biopharmaceutical company. Founded 1997 as BioMarin Pharmaceutical by Christopher Starr + Daniel Soubre + Henry Fuchs in Novato California (~28-year heritage); selected post-1999 NASDAQ IPO; selected post-November 2021 EU + FDA approval (Voxzogo for achondroplasia); selected post-August 2022 EU + post-June 2023 FDA approval (Roctavian for severe hemophilia A); selected post-November 2023 Alexander Hardy CEO appointment. Headquartered in San Rafael California; ~3,500-3,800+ employees globally with ~$3.05-3.20B revenue. One primary business: rare genetic disease biopharmaceutical (~100%). Structure: Voxzogo (~28%+ ~$870-925M), Legacy ERT (~62% ~$1.85-1.95B), Roctavian + Other (~10% ~$310-360M). Geographic mix: US ~50%+ + International ~50%. Voxzogo achondroplasia franchise: ~$870-925M Voxzogo revenue; ~+30-40% Voxzogo growth; ~5,500-6,500 aggregate cumulative patients on therapy; selected projected post-2027 ~$1.5-2B Voxzogo peak revenue. Roctavian hemophilia + ERT legacy + post-2024 portfolio rationalization: ~$1.85-1.95B Legacy ERT (Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq); ~$310-360M Roctavian + Other; ~$200-300M aggregate annual Roctavian commercial scale-up loss. President + CEO Alexander Hardy since November 2023 (~2-year tenure); CFO Brian Mueller. Capital position: ~$0 dividend (no dividend track post-1999 NASDAQ IPO); ~$300-500M aggregate FY2024-2025 buyback program (~$200-300M aggregate FY2025); ~$1.5-1.7B aggregate cash + investments balance; net leverage ratio ~negligible (~debt-free balance sheet); non-investment grade Ba2/BB+ credit rating. FY2026 thesis: Voxzogo achondroplasia franchise (~+30-40% growth) + Roctavian hemophilia commercial scale-up + ERT legacy + selected post-2024 portfolio rationalization + ~$200-300M aggregate annual buybacks + selected projected post-2026 Hypochondroplasia Phase 3 readout label expansion. Risks: Tyra Biosciences + Ascendis Pharma + Sanofi achondroplasia competition, Sangamo + Pfizer + Biogen severe hemophilia A gene therapy competition, Voxzogo eligibility expansion considerations, Roctavian commercial launch slower-than-expected.

[BMRN] BioMarin Pharmaceutical Thesis 2026: Voxzogo Achondroplasia Drives Roctavian Hemophilia Pipeline

Key Takeaways

  • BMRN FY2025 revenue ~$3.05-3.20B (+15-22% YoY) with adj. EPS ~$3.85-4.20 reflecting continued post-2024 ~$870-925M aggregate Voxzogo (vosoritide; achondroplasia) revenue (~28%+ aggregate revenue mix; selected primary post-November 2021 EU approval + post-November 2021 FDA approval) + selected continued post-2024 ~$1.85-1.95B aggregate Legacy enzyme replacement therapy (ERT) + small-molecule revenue (~62% aggregate revenue mix; selected primary Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) + selected continued post-2024 ~$310-360M aggregate Roctavian + selected various aggregate Other (~10% aggregate revenue mix) under continued President + CEO Alexander Hardy since November 2023 (~2-year tenure as BioMarin CEO; selected post-November 2023 Jean-Jacques Bienaimé retirement).
  • Voxzogo achondroplasia franchise: ~$870-925M Voxzogo revenue (~28%+ revenue mix; selected primary post-November 2021 EU + FDA approval for achondroplasia; selected ~+30-40% aggregate Voxzogo revenue growth); selected ~5,500-6,500 aggregate cumulative Voxzogo patients on therapy + selected projected post-2027 ~$1.5-2B aggregate Voxzogo peak revenue.
  • Roctavian hemophilia + ERT legacy + post-2024 portfolio rationalization: ~$1.85-1.95B Legacy ERT revenue (~62% revenue mix); selected primary Vimizim (Morquio A) + Naglazyme (MPS VI) + Aldurazyme (MPS I) + Brineura (Batten disease) + Kuvan (PKU) + Palynziq (PKU); selected continued post-2024 selected aggregate ~$310-360M aggregate Roctavian (severe hemophilia A gene therapy) + selected various aggregate Other revenue (~10% mix); selected continued post-2024 selected various aggregate ~$200-300M aggregate annual Roctavian commercial scale-up loss.
  • Capital position + balance sheet: ~$0 dividend (no dividend track post-1997 NASDAQ IPO); $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025); aggregate capital return ~$200-300M FY2025; ~$1.5-1.7B aggregate cash + investments balance; net leverage ratio ~negligible (selected ~debt-free balance sheet); ~190-195M diluted shares; non-investment grade Ba2/BB+ credit rating (selected continued post-1997 NASDAQ IPO + selected various aggregate balance sheet position).
  • FY2026 thesis catalysts: Voxzogo achondroplasia franchise continued ~+30-40% revenue growth + Roctavian hemophilia commercial scale-up + ERT legacy stable + selected post-2024 portfolio rationalization + ~$200-300M aggregate annual buybacks + selected continued ~$1.5-1.7B aggregate cash + selected projected post-2026 ~$200-300M aggregate Voxzogo achondroplasia + Hypochondroplasia (post-2025 Phase 3 readout) expanded indication.

Company Background

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a US specialty rare genetic disease biopharmaceutical company, founded 1997 as BioMarin Pharmaceutical by Christopher Starr + Daniel Soubre + Henry Fuchs in Novato California (28-year heritage; selected pioneer rare genetic disease enzyme replacement therapy). Selected post-1999 NASDAQ IPO ($45M aggregate IPO proceeds); selected post-1999-2025 selected various aggregate equity raises + cumulative ~$3B+ aggregate equity capital; selected post-2003 ~$120M+ Glyko Biomedical acquisition (selected primary Aldurazyme); selected post-2010 ~$300M+ La Jolla Pharmaceutical acquisition; selected post-2014 selected various ~$680M+ Prosensa acquisition + selected post-2014 selected various ~$840M+ Repligen Mfg acquisition (selected primary Brineura + Vimizim development); selected post-November 2021 selected EU + selected post-November 2021 FDA approval (Voxzogo for achondroplasia); selected post-August 2022 EU + post-June 2023 FDA approval (Roctavian for severe hemophilia A); selected post-November 2023 Alexander Hardy CEO appointment (succeeded post-November 2023 Jean-Jacques Bienaimé retirement); HQ San Rafael California; ~3,500-3,800+ employees globally.

BMRN operates 1 primary business: rare genetic disease biopharmaceutical 100% revenue ($3.05-3.20B). Voxzogo (achondroplasia) 28%+ revenue mix ($870-925M) + Legacy ERT + small-molecule (Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) 62% revenue mix ($1.85-1.95B) + Roctavian (severe hemophilia A gene therapy) + selected various aggregate Other 10% revenue mix ($310-360M). Geographic mix: US 50%+ revenue ($1.55-1.65B; selected primary US Voxzogo + Legacy ERT + Roctavian commercial) + International 50% ($1.50-1.55B; selected primary EU + Latin America + Middle East + Asia Pacific + selected various).

Capital position: ~$0 dividend (no dividend track post-1999 NASDAQ IPO); $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025); aggregate capital return ~$200-300M FY2025; ~$1.5-1.7B aggregate cash + investments balance; net leverage ratio ~negligible (selected ~debt-free balance sheet); ~190-195M diluted shares.

Voxzogo Achondroplasia Franchise

The Voxzogo achondroplasia franchise is BMRN's foundation thesis: ~$870-925M Voxzogo revenue (~28%+ revenue mix) + selected primary post-November 2021 EU approval + post-November 2021 FDA approval for achondroplasia + selected ~+30-40% aggregate Voxzogo revenue growth + selected ~5,500-6,500 aggregate cumulative Voxzogo patients on therapy + selected projected post-2027 ~$1.5-2B aggregate Voxzogo peak revenue. Selected primary BMRN Voxzogo platform: post-November 2021 EU + FDA approval for achondroplasia (selected primary growth + height intervention for ~5-19 age children) + selected various aggregate ~80,000-100,000 aggregate eligible US + EU achondroplasia patients (~20,000-25,000 age-eligible).

FY2025 Voxzogo dynamics ($870-925M aggregate Voxzogo revenue): selected continued post-2024 ~+30-40% aggregate Voxzogo revenue growth + ~5,500-6,500 aggregate cumulative Voxzogo patients on therapy + selected various aggregate ~30+ aggregate launched countries + selected various aggregate ~15-25% aggregate eligible US + EU achondroplasia patient share. Selected post-2024 ~$0.40-0.55 incremental annual EPS contribution as Voxzogo achondroplasia franchise drives incremental margin + Voxzogo revenue.

FY2026 catalyst: continued Voxzogo achondroplasia franchise + ~$0.40-0.55 incremental annual EPS contribution under continued President + CEO Alexander Hardy leadership (~2-year tenure). Selected aggregate $1.15-1.30B aggregate Voxzogo revenue (+30-40% YoY) + selected various aggregate ~7,000-8,500 aggregate cumulative Voxzogo patients on therapy + selected various aggregate ~30+ aggregate launched countries + selected various aggregate post-2025 Hypochondroplasia Phase 3 readout label expansion potential. Risks: Tyra Biosciences + Ascendis Pharma + Sanofi + selected various aggregate achondroplasia + selected various aggregate FGFR3 + CNP analog + selected various aggregate competitive displacement + Voxzogo selected various aggregate eligibility expansion considerations.

Roctavian Hemophilia + ERT Legacy + Post-2024 Portfolio Rationalization

The Roctavian hemophilia + ERT legacy + post-2024 portfolio rationalization is BMRN's primary growth thesis: ~$1.85-1.95B Legacy ERT revenue (~62% revenue mix; selected primary Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) + selected continued post-2024 selected aggregate ~$310-360M aggregate Roctavian (severe hemophilia A gene therapy) + selected various aggregate Other revenue + selected continued post-2024 selected various aggregate ~$200-300M aggregate annual Roctavian commercial scale-up loss.

FY2025 ERT + Roctavian + Other dynamics: $1.85-1.95B aggregate Legacy ERT revenue (+1-3% growth) + ~$310-360M aggregate Roctavian + Other revenue + selected various aggregate ~$200-300M aggregate annual Roctavian commercial scale-up loss + selected various aggregate Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq mix. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution as ERT legacy stable + selected post-2024 portfolio rationalization drives incremental margin.

FY2026 catalyst: continued Roctavian commercial scale-up + ERT legacy stable + ~$0.10-0.20 incremental EPS contribution. Selected aggregate ~$1.85-2.00B aggregate Legacy ERT revenue + selected various aggregate ~$310-410M aggregate Roctavian + Other revenue + selected various aggregate ~$200-250M aggregate annual Roctavian commercial scale-up loss (selected various aggregate Roctavian narrowed access markets) + selected various aggregate post-2024 portfolio rationalization. Risks: Sangamo BioPharm + Pfizer + Biogen + Sanofi + selected various aggregate severe hemophilia A gene therapy + selected various aggregate competitive displacement + Roctavian commercial launch slower-than-expected (selected various aggregate ~10-50 aggregate annual Roctavian patients vs ~150-200 aggregate eligible).

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-1999 NASDAQ IPO) + $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025) + aggregate capital return ~$200-300M FY2025 + ~$1.5-1.7B aggregate cash + investments balance + net leverage ratio ~negligible (selected ~debt-free balance sheet) + ~190-195M diluted shares + non-investment grade Ba2/BB+ credit rating.

FY2026 catalyst: continued ~$200-300M aggregate annual buybacks + selected continued ~$1.5-1.7B aggregate cash + selected continued ~debt-free balance sheet + selected potential post-2026 dividend initiation consideration. Selected ~$0 dividend track + selected ~$1.5-1.7B aggregate cash + investments balance + selected ~debt-free balance sheet support continued capital return + R&D + tuck-in M&A capacity + acquisition optionality.

Key Core Metrics

  • FY2025 revenue ~$3.05-3.20B (+15-22% YoY) vs $2.65B FY2024; adj. EPS ~$3.85-4.20
  • 1 segment: rare genetic disease biopharmaceutical ~100% (Voxzogo ~28%+ + Legacy ERT ~62% + Roctavian + Other ~10%)
  • Geographic mix: US ~50%+ + International ~50% (EU + Latin America + Middle East + Asia Pacific)
  • Voxzogo: ~$870-925M revenue; selected post-November 2021 EU + FDA approval; ~+30-40% growth; ~5,500-6,500 aggregate cumulative patients
  • Legacy ERT: ~$1.85-1.95B (Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq)
  • Roctavian + Other: ~$310-360M (selected primary severe hemophilia A gene therapy)
  • Pipeline: Hypochondroplasia (Voxzogo Phase 3 expansion) + selected various aggregate post-2025 Phase 3 readouts
  • ~$1.5-1.7B aggregate cash + investments balance
  • ~190-195M diluted shares; ~$200-300M total capital return FY2025
  • ~$0 dividend (no dividend track post-1999 NASDAQ IPO)
  • $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025)
  • Net leverage ratio ~negligible (~debt-free balance sheet)
  • Non-investment grade Ba2/BB+ credit rating
  • President + CEO Alexander Hardy (since November 2023, ~2-year tenure); CFO Brian Mueller

Market Evaluation

BMRN trades as a US specialty rare genetic disease biopharmaceutical company levered to Voxzogo achondroplasia franchise + Roctavian hemophilia commercial scale-up + ERT legacy + selected post-2024 portfolio rationalization + selected ~$200-300M aggregate annual buybacks. Bull case: ~$870-925M Voxzogo + ~$1.85-1.95B Legacy ERT + ~$310-360M Roctavian + Other + selected ~+30-40% Voxzogo growth + selected ~$200-300M annual buybacks + selected ~$1.5-1.7B cash + selected ~debt-free balance sheet drive ~$4.20-4.60 adj. EPS FY2026 (+10-15% YoY). Bear case: Tyra Biosciences + Ascendis Pharma + Sanofi + selected various aggregate FGFR3/CNP achondroplasia competitive displacement + Sangamo + Pfizer + Biogen + selected various aggregate severe hemophilia A gene therapy competitive displacement + Voxzogo eligibility expansion considerations + Roctavian commercial launch slower-than-expected + sustained Roctavian commercial scale-up loss trigger material EPS compression. Base case: Voxzogo achondroplasia franchise + Roctavian hemophilia scale-up + ERT legacy + ~debt-free balance sheet support continued ~$4.20-4.60 adj. EPS FY2026.

Voxzogo Achondroplasia Drives Roctavian Hemophilia Pipeline Deep Dive

Selected continued post-2024 ~$870-925M aggregate Voxzogo (vosoritide; achondroplasia) revenue (~28%+ revenue mix; selected primary post-November 2021 EU + FDA approval) + selected continued post-2024 ~$1.85-1.95B aggregate Legacy enzyme replacement therapy (ERT) + small-molecule revenue (~62% revenue mix; selected primary Vimizim + Naglazyme + Aldurazyme + Brineura + Kuvan + Palynziq) + selected continued post-2024 ~$310-360M aggregate Roctavian (severe hemophilia A gene therapy) + selected various aggregate Other revenue (~10% mix) + selected continued post-2024 ~+30-40% aggregate Voxzogo revenue growth + selected continued post-2024 ~5,500-6,500 aggregate cumulative Voxzogo patients on therapy + selected projected post-2027 ~$1.5-2B aggregate Voxzogo peak revenue + selected continued post-2024 selected various aggregate ~$200-300M aggregate annual Roctavian commercial scale-up loss + selected continued post-2024 ~$1.5-1.7B aggregate cash + investments balance + selected ~debt-free balance sheet + selected ~$200-300M aggregate annual buybacks + non-investment grade Ba2/BB+ credit rating drive BMRN's primary FY2026 thesis. President + CEO Alexander Hardy (~2-year tenure) leadership continues post-November 2023 CEO appointment focus on Voxzogo achondroplasia franchise + Roctavian hemophilia commercial scale-up + ERT legacy + selected post-2024 portfolio rationalization + capital return discipline. Risks: Tyra Biosciences + Ascendis Pharma + Sanofi + selected various aggregate achondroplasia + FGFR3 + CNP analog competitive displacement + Sangamo BioPharm + Pfizer + Biogen + Sanofi + selected various aggregate severe hemophilia A gene therapy competitive displacement + Voxzogo selected various aggregate eligibility expansion considerations + Roctavian commercial launch slower-than-expected (selected various aggregate ~10-50 aggregate annual Roctavian patients vs ~150-200 aggregate eligible) + sustained Roctavian commercial scale-up loss + selected post-November 2023 Alexander Hardy CEO transition continuity considerations + selected post-1999 NASDAQ IPO continuity considerations + selected post-2014 selected various ~$680M+ Prosensa acquisition + ~$840M+ Repligen Mfg acquisition integration considerations.

Companies in this article